Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3)

Trends in Immunology

Volumn 31, Issue 1, 2010, Pages 24-31

  Beurel, Eléonore ^a   Michalek, Suzanne M ^b   Jope, Richard S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; LITHIUM; SMAD PROTEIN; STAT PROTEIN; TRANSCRIPTION FACTOR NFAT;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BIPOLAR DISORDER; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLITIS; CYTOKINE PRODUCTION; ENZYME INHIBITION; HUMAN; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NONHUMAN; PERITONITIS; REVIEW; SEPSIS; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNITY, INNATE; LITHIUM; SIGNAL TRANSDUCTION;

EID: 73149097234     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2009.09.007     Document Type: Review

References (87)

1. Jope R.S., and Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2004) 95-102
2. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 8455-8459
3. Martin M., et al. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6 (2005) 777-784
4. Lin C.F., et al. IFN-γ synergizes with LPS to induce nitric oxide biosynthesis through glycogen synthase kinase-3-inhibited IL-10. J. Cell. Biochem. 105 (2008) 746-755
5. Beurel E., and Jope R.S. Glycogen synthase kinase-3 promotes the synergistic action of interferon-γ on lipopolysaccharide-induced IL-6 production in RAW264.7 cells. Cell. Signal. 21 (2009) 978-985
6. Tsai C.C., et al. Glycogen synthase kinase-3β facilitates IFN-γ-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2. J. Immunol. 183 (2009) 856-864
7. Chan M.M., et al. A role for glycogen synthase kinase-3 in antagonizing mycobacterial immune evasion by negatively regulating IL-10 induction. J. Leukoc. Biol. 86 (2009) 283-291
8. Hu X., et al. IFN-γ suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24 (2006) 563-574
9. Rehani K., et al. Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2. J. Immunol. 182 (2009) 547-553
10. Wang H., et al. IFN-β production by TLR4-stimulated innate immune cells is negatively regulated by GSK3-β. J. Immunol. 181 (2008) 6797-6802
11. Aoukaty A., and Tan R. Role for glycogen synthase kinase-3 in NK cell cytotoxicity and X-linked lymphoproliferative disease. J. Immunol. 174 (2005) 4551-4558
12. Ohtani M., et al. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood 112 (2008) 635-643
13. Rodionova E., et al. GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood 109 (2007) 1584-1592
14. Shen F., et al. IL-17 receptor signaling inhibits C/EBPβ by sequential phosphorylation of the regulatory 2 domain. Sci. Signal. 2 (2009) ra8
15. Shen E., et al. Glycogen synthase kinase-3β suppresses tumor necrosis factor-α expression in cardiomyocytes during lipopolysaccharide stimulation. J. Cell. Biochem. 104 (2008) 329-338
16. Vines A., et al. Novel anti-inflammatory role for glycogen synthase kinase-3β in the inhibition of tumor necrosis factor-α- and interleukin-1β-induced inflammatory gene expression. J. Biol. Chem. 281 (2006) 16985-16990
17. Jing H., et al. A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2. J. Biol. Chem. 279 (2004) 55176-55186
18. 2. Biochem. Pharmacol. 73 (2007) 843-853
19. Yuskaitis C.J., and Jope R.S. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell. Signal. 21 (2009) 264-273
20. Cuzzocrea S., et al. Effects of glycogen synthase kinase-3β inhibition on the development of cerulein-induced acute pancreatitis in mice. Crit. Care Med. 35 (2007) 2811-2821
21. Skov S., et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 65 (2005) 11136-11145
22. Xu Y., et al. CIITA mediates interferon-γ repression of collagen transcription through phosphorylation-dependent interactions with co-repressor molecules. J. Biol. Chem. 283 (2008) 1243-1256
23. Cai X., et al. Glycogen synthase kinase 3- and extracellular signal-regulated kinase-dependent phosphorylation of paxillin regulates cytoskeletal rearrangement. Mol. Cell. Biol. 26 (2006) 2857-2868
24. Jope R.S., et al. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 32 (2007) 577-595
25. Wood J.E., et al. TcR and TcR-CD28 engagement of protein kinase B (PKB/AKT) and glycogen synthase kinase-3 (GSK-3) operates independently of guanine nucleotide exchange factor VAV-1. J. Biol. Chem. 281 (2006) 32385-32394
26. Appleman L.J., et al. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 168 (2002) 2729-2736
27. + T cell responses. J. Immunol. 181 (2008) 8363-8371
28. Neilson J., et al. Monitoring the duration of antigen-receptor occupancy by calcineurin/glycogen-synthase-kinase-3 control of NF-AT nuclear shuttling. Curr. Opin. Immunol. 13 (2001) 346-350
29. Diehn M., et al. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11796-11801
30. Sengupta S., et al. Unrestrained glycogen synthase kinase-3β activity leads to activated T cell death and can be inhibited by natural adjuvant. J. Immunol. 178 (2007) 6083-6091
31. Ohteki T., et al. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J. Exp. Med. 192 (2000) 99-104
32. De Sarno P., et al. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 181 (2008) 338-345
33. Lambert S.L., and Martinez O.M. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J. Immunol. 179 (2007) 8225-8234
34. Varrin-Doyer M., et al. Phosphorylation of collapsin response mediator protein 2 on Tyr-479 regulates CXCL12-induced T lymphocyte migration. J. Biol. Chem. 284 (2009) 13265-13276
35. Wu B., et al. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 26 (2007) 227-239
36. Gounari F., et al. Somatic activation of β-catenin bypasses pre-TCR signaling and TCR selection in thymocyte development. Nat. Immunol. 2 (2001) 863-869
37. + thymocyte survival. Nat. Immunol. 2 (2001) 691-697
38. Ding Y., et al. β-Catenin stabilization extends regulatory T cell survival and induces anergy in nonregulatory T cells. Nat. Med. 14 (2008) 162-169
39. + memory stem cells. Nat. Med. 15 (2009) 808-813
40. Welsh G.I., et al. T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3. J. Biol. Chem. 271 (1996) 11410-11413
41. Miller A.H., et al. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65 (2009) 732-741
42. Rivest S. Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 9 (2009) 429-439
43. Hua F., et al. Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion. J. Neuroimmunol. 190 (2007) 101-111
44. Chuang D.M. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann. N. Y. Acad. Sci. 1053 (2005) 195-204
45. Collino M., et al. Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3β. Diabetes 58 (2009) 235-242
46. Beurel E., and Jope R.S. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J. Neuroinflamm. 6 (2009) 9-20
47. Hashioka S., et al. Antidepressants inhibit interferon-γ-induced microglial production of IL-6 and nitric oxide. Exp. Neurol. 206 (2007) 33-42
48. Huang W.C., et al. Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology 128 (2009) e275-e286
49. Beurel E., and Jope R.S. Differential regulation of STAT family members by glycogen synthase kinase-3. J. Biol. Chem. 283 (2008) 21934-21944
50. Chong Z.Z., et al. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3β and nuclear factor-κB to foster endogenous microglial cell protection. Int. J. Mol. Med. 19 (2007) 263-272
51. Li F., et al. Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3β, β-catenin, and nuclear factor-κB. Curr. Neurovasc. Res. 3 (2006) 187-201
52. Cuzzocrea S., et al. Glycogen synthase kinase-3β inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin. Immunol. 120 (2006) 57-67
53. Dugo L., et al. GSK-3β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit. Care Med. 33 (2005) 1903-1912
54. Bao Z., et al. Glycogen synthase kinase-3β inhibition attenuates asthma in mice. Am. J. Respir. Crit. Care Med. 176 (2007) 431-438
55. Evenson A.R., et al. GSK-3β inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. Int. J. Biochem. Cell. Biol. 37 (2005) 2226-2238
56. Whittle B.J., et al. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3β. Br. J. Pharmacol. 147 (2006) 575-582
57. Dugo L., et al. Glycogen synthase kinase-3β inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock 25 (2006) 485-491
58. Zhu M., et al. Glycogen synthase kinase 3β and β-catenin are involved in the injury and repair of bronchial epithelial cells induced by scratching. Exp. Mol. Pathol. 83 (2007) 30-38
59. Gao H.K., et al. Glycogen synthase kinase 3 inhibition protects the heart from acute ischemia-reperfusion injury via inhibition of inflammation and apoptosis. J. Cardiovasc. Pharmacol. 52 (2008) 286-292
60. Wang Y., et al. Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal failure by down-regulating inflammation and renal cell apoptosis. Br. J. Pharmacol. 157 (2009) 1004-1013
61. Lenz S.P., et al. Lithium chloride enhances survival of NZB/W lupus mice: influence of melatonin and timing of treatment. Int. J. Immunopharmacol. 17 (1995) 581-592
62. Zhang P., et al. Glycogen synthase kinase-3β (GSK3β) inhibition suppresses the inflammatory response to Francisella infection and protects against tularemia in mice. Mol. Immunol. 46 (2009) 677-687
63. Cuzzocrea S., et al. Glycogen synthase kinase-3β inhibition reduces secondary damage in experimental spinal cord trauma. J. Pharmacol. Exp. Ther. 318 (2006) 79-89
64. Weiner H.L. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 255 Suppl. 1 (2008) 3-11
65. Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med. Res. Rev. 28 (2008) 773-796
66. Beurel E., and Jope R.S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog. Neurobiol. 79 (2006) 173-189
67. Steinbrecher K.A., et al. Glycogen synthase kinase 3β functions to specify gene-specific, NF-κB-dependent transcription. Mol. Cell. Biol. 25 (2005) 8444-8455
68. Buss H., et al. Phosphorylation of serine 468 by GSK-3β negatively regulates basal p65 NF-κB activity. J. Biol. Chem. 279 (2004) 49571-49574
69. Saijo K., et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137 (2009) 47-59
70. Clifford R.L., et al. Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factorβ1: requirement for Smads, β-catenin, and GSK3β. J. Biol. Chem. 283 (2008) 35337-35353
71. Guo X., et al. Axin and GSK3β control Smad3 protein stability and modulate TGFβ signaling. Genes Dev. 22 (2008) 106-120
72. Liang M.H., et al. Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol. Cell. Neurosci. 37 (2008) 440-453
73. Duan Y., et al. β-Catenin activity negatively regulates bacteria-induced inflammation. Lab. Invest. 87 (2007) 613-624
74. Christian S.L., et al. The B cell antigen receptor regulates the transcriptional activator β-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3. J. Immunol. 169 (2002) 758-769
75. Pan M., et al. Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation. J. Immunol. 178 (2007) 4315-4321
76. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol. Psychiatry 4 (1999) 117-128
77. Jope R.S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 24 (2003) 441-443
78. Phiel C.J., and Klein P.S. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 789-813
79. Doble B.W., and Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116 (2003) 1175-1186
80. Focosi D., et al. Lithium and hematology: established and proposed uses. J. Leukoc. Biol. 85 (2009) 20-28
81. Rybakowski J.K., et al. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 40 (1999) 134-139
82. Rapaport M.H., and Manji H.K. The effects of lithium on ex vivo cytokine production. Biol. Psychiatry 50 (2001) 217-224
83. Haack M., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res. 33 (1999) 407-418
84. Padmos R.C., et al. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 65 (2008) 395-407
85. Rao J.S., et al. Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol. Psychiatry 13 (2008) 585-596
86. Jafferany M. Lithium and skin: dermatologic manifestations of lithium therapy. Int. J. Dermatol. 47 (2008) 1101-1111
87. Jope, R.S. (2006) Lithium, the seminal GSK3 inhibitor. In Glycogen Synthase Kinase 3 (GSK-3) and its Inhibitors (Drug Discovery and Development) (Martinez, A. et al., eds) pp. 223-242, John Wiley and Sons